1 The valuation of disease-specific health states to facilitate economic evaluation E. Kok, E. Stolk, Jan J. v. Busschbach Address: –Jan v. Busschbach.

Slides:



Advertisements
Similar presentations
Comparing different treatments How can we decide?.
Advertisements

HEA PTP: M207 Health Economics1 Measurement & Valuation of Health What is health? Why do we need to measure it? How can it be measured? Why do we need.
Measuring outcomes Emma Frew October Measuring outcomes Learning objectives By the end of the session students should be able to – Explain how different.
Emma Frew Introduction to health economics, MSc HEHP, October 2012 Outcomes: part II.
Quality of life in relation to costs
Case 7:John Case 7: John Understanding BPH From the Science to the Clinical Setting.
1 Could there be a single European EQ tariff? Jan J.V. Busschbach, Ph.D. Former address: –iMTA, Erasmus university Present address: –Medical Psychology.
MODULE 5 1/30 Case 8: Craig. MODULE 5 Case 8: Craig 2/30 Patient History  Craig, a 56-year bank manager was recently referred to his urologist for consideration.
COCOM Kwaliteit van leven in maat en getal Jan van Busschbach.
Case 1: George Case 1: George
Supervised by: Dr- Al Traifi. Why LUTS? What are the symptoms? Common causes? Patient work up Details of the Common etiology BPH.
MODULE 5 1/33 Case 5: Sam. MODULE 5 Case 5: Sam 2/33 Patient History  Sam is a 66 year old retired painter & construction worker.  He is distressed.
MODULE 5 1/40 Case 3: Chuck. MODULE 5 Case 3: Chuck 2/40 Patient History  Chuck is a 66 year old retired chemical compounder  He is distressed by the.
1 The Future of Quality of Life Assessment in Cost-Effectiveness Research Prof. Jan J. v. Busschbach, Ph.D. Erasmus MC Medical Psychology and Psychotherapy.
MODULE 5 1/26 Case 6: Anthony. MODULE 5 Case 6: Anthony 2/26 Patient History  Anthony is a 55-year old lawyer.  He has been suffering from voiding complaints.
1 Does it make a difference for the patient? Survival & Quality of life  Jan J. v. Busschbach, Ph.D.  Erasmus MC Institute for Medical Psychology and.
1 A Health Economic View on Borderline Personality Disorder Prof. dr. Jan Busschbach Viersprong Institute for studies on Personality Disorders Medical.
Big Q and Little Q revisited Christopher McCabe PhD Capital Health Endowed Research Chair in Emergency Medicine Research.
(Cost-)Effectiveness of Psychotherapy for Personality Disorders Jan van Busschbach Prof. Dr. J. van Busschbach Department of Medical Psychology and Psychotherapy.
(Cost-)Effectiveness of Psychotherapy for Personality Disorders Prof. dr. Jan van Busschbach Department of Medical Psychology & Psychotherapy Erasmus MC.
MODULE 5 1/23 Case 9: Pierre. MODULE 5 Case 9: Pierre 2/23 Patient History  Pierre is 65 years of age who has suffered with benign prostatic hyperplasia.
Using a discrete choice experiment with duration to estimate values for health states on the QALY scale Nick Bansback Assistant Professor School of Population.
1 Interactive Introduction cost effectiveness Jan J. v. Busschbach, Ph.D. Psychotherapeutic Centrum ‘De Viersprong’, Halsteren
1 Cost-Effectiveness in Medicine An Interactive Introduction  Jan J. v. Busschbach, Ph.D.  Erasmus MC Institute for Medical Psychology and Psychotherapy.
A RECIPE FOR INCOHERENCE: AVERAGING TIME-TRADEOFF OR STANDARD-GAMBLE UTILITIES ACROSS HEALTH ATTRIBUTES Gordon B. Hazen, IEMS Department, Northwestern.
Lower urinary tract symptoms (LUTS) in elderly males
1 Dyslexia and Cost Effectiveness Prof. dr. Jan van Busschbach De Viersprong Erasmus MC.
2008. Causes of symptoms  Hyperplasia of epithelial and stromal components of prostate  Progressive obstruction of urinary outflow  Increased activity.
1 EuroQol EQ-5D Jan J. V. Busschbach, Ph.D Psychotherapeutic Centrum ‘De Viersprong’, Halsteren Department of Medical.
By: Ashley Whiteaker Benign Prostatic Hyperplasia In The Urinary System.
1 EQ-5D, HUI and SF-36 Of the shelf instruments…..
1 Health Economics  Comparing different allocations  Should we spent our money on Wheel chairs Screening for cancer  Comparing costs  Comparing outcome.
Overview of the EQ-5D Purpose and origins of the descriptive system.
1 The valuation of disease-specific questionnaires for QALY analysis  To rescue data in absence of an utility measure  Growth hormone deficiency in adults.
Dr Charles Chabert Urinary Symptoms &GreenLight Laser Prostatectomy.
Is healthcare any good for patients? Measuring health outcomes using EQ-5D Professor Paul Kind Principal Investigator Outcomes Research Group Centre for.
Rescuing Clinical Trial Data For Economic Evaluation
Economic evaluation of health programmes Department of Epidemiology, Biostatistics and Occupational Health Class no. 11: Cost-utility analysis – Part 4.
Measuring Health Outcomes
Why use the EQ-5D? What are the alternatives?. What are the alternatives for Direct valuation? Other VAS Time Trade-Off Standard Gamble Willingness to.
EQ-5D AND QUALITY OF LIFE OF OSTEOPOROSIS AT-RISK PATIENTS IN A SWEDISH OSTEOPOROSIS PATIENT REGISTRY Arun Krishna 1, Dan Mellström 2, Zhiyi Li 3, Chun-Po.
1 Reconciliation of Economic Arguments and Clinical Practice Monday November 4, 2002 ISPOR, Rotterdam Jan Busschbach PhD, –Department of Medical Psychology.
1 Patient values or values from the general public.
Decision Analysis Dr M G Dawes Centre for Evidence Based Medicine.
Interactive Introduction cost effectiveness Jan J. v. Busschbach, Ph.D Viersprong Institute for studies on Personality Disorders (VISPD)
1 Cost effectiveness as argument for reimbursement in prevention Jan J. v. Busschbach, Ph.D. Erasmus MC –Institute for Medical Psychology and Psychotherapy.
1 Interactive introduction in Quality of life Assessment Jan J. v. Busschbach, Ph.D. Department of Medical Psychology and Psychotherapy, Erasmus MC
1 EQ-5D, HUI and SF-36 Of the shelf instruments…..
The experience of Denmark with Summary Measures of Population Health 7 th Meeting of the Task Force on Health Expectancies Luxembourg, 2 December 2008.
Patsi Sinnott, PT, PhD, MPH HERC Economics Course April 7, 2010 Introduction to Effectiveness, Patient Preferences and Utilities.
Quality of life and Cost-Effectiveness An Interactive Introduction Prof. Jan J. v. Busschbach, Ph.D. Erasmus MC Medical Psychology and Psychotherapy Viersprong.
1 Scale recalibration effects in dementia patients and their proxies Sander Arons Dept. of Epidemiology, Biostatistics and HTA Radboud University Nijmegen.
Cost-Effectiveness of Psychotherapy for Personality Disorders Soeteman, Busschbach, Verheul.
Cost-effectiveness in the quest to convince the outside world Dr. Jan Busschbach De Viersprong Erasmus MC
1 Health outcome valuation study in Thailand Sirinart Tongsiri Research degree student Health Services Research Unit, Public Health & Policy Department.
1 Interactive Introduction Cost Effectiveness and Psychotherapy Jan J. v. Busschbach, Ph.D. Psychotherapeutic Centrum ‘De Viersprong’, Halsteren
1 The Economics of Health Care and New Technologies Friday October 18, 2002 Between Technology and Humanity, Brussels Jan Busschbach PhD, –Department of.
Hermann P. G. Schneider, Alastair H. MacLennan and David Feeny
“Introduction to Patient Preference Methods used for QALYs” Presented by: Jan Busschbach, PhD, Chair Section Medical Psychology and Psychotherapy, Department.
Cost-Effectiveness of Psychotherapy (for Personality Disorders) Prof. dr. Jan van Busschbach.
Values Lower Than Death Jan J. v. Busschbach, Ph.D. –Erasmus University Rotterdam institute for Medical Technology Assessment (iMTA) PO box DR.
(Cost-)Effectiveness of Psychotherapy for Personality Disorders Jan van Busschbach Prof. Dr. J. van Busschbach Department of Medical Psychology and Psychotherapy.
1 Quality of life and Cost-Effectiveness An Interactive Introduction Prof. Jan J. v. Busschbach, Ph.D. Erasmus MC Medical Psychology and Psychotherapy.
Who is involved in making NICE guidance recommendations and what evidence do they look at? Heidi Livingstone, Senior Public Involvement Adviser.
1 Cost-Effectiveness in Medicine An Interactive Introduction  Jan J. v. Busschbach, Ph.D.  Erasmus MC Institute for Medical Psychology and Psychotherapy.
1 RTOG 1115 Health Related Quality of Life and Comparative Effectiveness Deborah Watkins Bruner, RN, PhD, FAAN.
1 Utilization of Quality of Life Research in Decision-Making and Policy  Prof. Dr. Jan J.V. Busschbach  Erasmus MC, Rotterdam, The Netherlands  Section.
Prof. Dr. Jan J.V. Busschbach
The valuation of disease-specific questionnaires for QALY analysis
Measuring outcomes Emma Frew October 2012.
Presentation transcript:

1 The valuation of disease-specific health states to facilitate economic evaluation E. Kok, E. Stolk, Jan J. v. Busschbach Address: –Jan v. Busschbach Erasmus University Rotterdam institute for Medical Technology Assessment (iMTA) PO box DR Rotterdam (secretariat) (fax)

2 Quality of life measurement in health economics Preferred outcome: QALY Preferred perspective: societal –Values from the general public –Values for imaginable health states »(usually) not one own health state QALYS are often measured with standard questionnaires –HUI or EQ-5D: standardized, validated –Generic quality of life questionnaires Unfortunately, generic questionnaires are not sensitive for disease specific items

3 Is EQ-5D sensitive in BPH? MOBILITY –I have no problems in walking about –I have some……. –I am confined to bed SELF-CARE –I have no problems with self-care –I have some problems….. –I am unable… USUAL ACTIVITIES –I have no problems with performing my usual activities –I have some problems… –I am unable…. PAIN/DISCOMFORT –I have no pain or discomfort –I have moderate ….. –I have extreme…….. ANXIETY/DEPRESSION –I am not anxious or depressed –I am moderately…….. –I am extremely….. Not sensitive for BPH BPH –Enlargement of the prostate –Causes voiding problems in elderly men »Difficulties to pee –Cure »Operations »New medicine suppress symptoms

4 International Symptom Prostate Score The IPSS is often used as out come measure –Seen as valid and sensitive 7 questions: How often have you –had to push or strain to begin urination? –had a sensation of not emptying your bladder completely? –had to urinate again less than two hours after you finished urinating? –found you stopped and started again several times when you urinated? –you find it difficult to postpone urination? –had a weak urinary stream? –How many times did you most typically get up to urinate from the time you went to bed at night until the time you got up in the morning? 6 answer levels –0 = not at all (none) –1 = seldom (one time) –2 = less than half the time (two times) –3 = about half the time (three times) –4 = more than half the time (four times) –5 = almost always (five or more times)

5 Can we convert the IPSS outcomes into utilities? Attribute TTO values to the IPSS health states Problem: IPSS has health states –7 items, 6 answer levels = 6 7 = –Too many to value with TTO Reduce number of health states –Reduce items »Factor analysis –Reduce answer levels »Combine answer levels

6 Factor analysis on patients IPSS responses –N = 1414 Two main factors –Obstructive (alpha= ) –Irritative (alpha= ) »Confirmed in literature Factors divided in 3 levels Number of health states reduced to 3 3 = 9 –Can be valued directly TTO –General public, representative for gender/age (N=170) Reduce number of health states

7 QALY weights for BPH

8 How to come to these values?

9 Treatment-effect

10 How to interpret disease specific utilities Only the disutility of the specific disease is valued Generic and specific utilities are not on the same scale –Generic top anchor: absence of any impairment –Specific top anchor: absence of specific impairment »Co morbidity might still be present Value of life years “traded off” in TTO differ –Healthy subject:1 life year is 1.0 QALY –Sick subject:1 life year is 0.5 QALY –Life years of healthy persons are more worth than those of sick Correction for co morbidity needed

11 Specific values should be corrected for average morbidity Overall health states influence disutility –20% trade off at 1.00: disutility = 0.20 –20% trade off at 0.80: disutility = 0.16 –20% trade off at 0.60: disutility = 0.12 Raw specific trade-off might overestimated gains –Also counts for so called “scenarios” –Overestimated CE-ration by 15% using specific utilities »Proposed by Fryback & Lawrence, MDM 1997 »For not completely the same problem… »…for own health states, not imaginable health states

12 Solution: multiplicative model Related specific utilities to generic –Values of the IPSS have to be multiplied by average value for age group. »For instance male age 55-64: overall QoL utility: 0.81 »Most severe BPH: 0.87 »Male age with most severe BPH: 0.81 x 0.87 =.7047 Maximum gain reduces from –Raw score = 0.13 –Adjust score = 0.11 –15 % reduction

13 We validated the IPSS for the use in economic appraisal –Now, IPSS has QALY-weights –New and already published research can be converted into QALYs Many other applications possible –Also in erectile dysfunction and diabetic foot ulcers Advantage use specific QALYs measures –High sensitive disease specific measures for QALY-analysis Disadvantages –± 15 % correction needed Conclusion